

Supplementary Figure S4. Subgroup analysis of confirmed ORR by PD-L1 TC and IC expression for (A) durvalumab plus EP versus EP and (B) durvalumab plus tremelimumab plus EP versus EP. In each panel, the shaded band shows the confidence interval for the ITT population; circle sizes are proportional to the number of responses. Groups are not plotted when there are ≤5 responses across both arms. BEP, biomarker-evaluable population; CI, confidence interval; D, durvalumab; EP, platinum-etoposide; IC, immune cell; ITT, intention-to-treat; ORR, objective response rate; PD-L1, programmed cell death ligand-1; T, tremelimumab; TC, tumor cell.



Number of with res	•	
D+EP	EP	Odds ratio (95% CI)
182 / 268	156 / 269	1.53 (1.08–2.18)
106 / 152	67 / 129	2.14 (1.32–3.51)
80 / 117	50 / 101	2.21 (1.28–3.85)
26 / 35	17 / 28	1.87 (0.64–5.58)
104 / 145	64 / 121	2.26 (1.36–3.77)
2/7	3/8	0.67 (0.06–5.87)
79 / 114	48 / 97	2.30 (1.32-4.07)
27 / 38	19/32	1.68 (0.62-4.61)



Number of patients with response			
	D+T+EP	EP	Odds ratio (95% CI)
	156 / 267	156 / 269	1.02 (0.72–1.44)
	88 / 157	67 / 129	1.18 (0.74–1.89)
	60 /107	50 / 101	1.30 (0.75–2.25)
	28 / 50	17 / 28	0.82 (0.32-2.10)
	81 / 147	64 / 121	1.09 (0.67–1.77)
	7 / 10	3 / 8	3.89 (0.58–32.28)
	56 / 103	48 / 97	1.22 (0.70-2.12)
	32 / 54	19 / 32	1.00 (0.40-2.42)